1. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries;Post;ESMO Open,2023
2. European Medicines Agency. Centralized Procedure. Available at: https://www.ema.europa.eu/en/glossary/centralised-procedure; Accelerated Assessment. Available at: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment; PRIME: priority medicines. Available at: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment; Compassionate Use. Available at: 〈https://www.ema.europa.eu/en/human-regulatory/research-development/compassionate-use〉.
3. EU Clinical Trials Regulation No 536/2014. Available at 〈https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trials-regulation〉.
4. . EFPIA patients w.a.i.t. indicator 2021 survey, updated July 2022. Available at 〈https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf〉.
5. Differences in time to patient access to innovative cancer medicines in six European countries;Vancoppenolle;Int J. Cancer,2023